🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

Roth/MKM sets stock target on CervoMed, buy rating on strong trial results

EditorNatashya Angelica
Published 12/06/2024, 09:18 AM
CRVO
-

On Friday, Roth/MKM initiated coverage on shares of CervoMed (NASDAQ:CRVO), a pharmaceutical company, with a Buy rating and a 12-month price target of $45.00. The firm's positive outlook is based on a discounted cash flow (DCF) analysis and the potential market impact of the company's leading drug candidate, neflamapimod.

The analyst highlighted the efficacy of neflamapimod, which is currently being tested in a Phase 2a study for patients with pure Dementia with Lewy Bodies (DLB). The study, which involved 11 participants, showed promising results.

Moreover, the analyst expressed optimism for the upcoming Phase 2b study results, expected in the fourth quarter of 2024. If the data is positive, this could position CervoMed as a first mover in the market with significant revenue potential, projecting more than $1 billion by 2034.

CervoMed's financial position was also noted, with the management expecting the company's cash reserves to last through the year 2025. The company reported having $46.7 million at the end of the third quarter of 2024. The analyst anticipates that the company may seek equity financing following the positive outcome of the Phase 2b data.

The endorsement from Roth/MKM comes at a critical juncture for CervoMed as it advances through the clinical trial process. The company's progress and the anticipation for future study results are key factors in the analyst's recommendation.

CervoMed's stock is now under the spotlight as investors and industry watchers await the Phase 2b trial readout, which could be a pivotal moment for the company's drug neflamapimod and its future in the DLB treatment landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.